-
1
-
-
84907283727
-
-
American Academy of Pain Medicine. Accessed August 13
-
American Academy of Pain Medicine. http://www.painmed.org/patientcenter/facts-on-pain.aspx#refer. Accessed August 13, 2013
-
(2013)
-
-
-
2
-
-
80053201781
-
-
Relieving pain in America, a Blueprint for Transforming, Prevention, Care, Education and Research The National Academies Press, Washington DC
-
Relieving pain in America, a Blueprint for Transforming, Prevention, Care, Education and Research. Institute of Medicine Report from the Committee on Advancing Pain Research, The National Academies Press, Washington, DC. 2011.
-
(2011)
Institute of Medicine Report from the Committee on Advancing Pain Research
-
-
-
3
-
-
67650755014
-
A comparison of long-and short-acting opioids for the treatment of chronic noncancer pain: Tailoring therapy to meet patient needs
-
Argoff C, Silvershein D. A comparison of long-and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clinic Proc 2009;84:602-12
-
(2009)
Mayo Clinic Proc
, vol.84
, pp. 602-612
-
-
Argoff, C.1
Silvershein, D.2
-
4
-
-
58949087497
-
Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain
-
Chou R, Fanciullo G, Fine P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30
-
(2009)
J Pain
, vol.10
, pp. 113-130
-
-
Chou, R.1
Fanciullo, G.2
Fine, P.3
-
5
-
-
84907283726
-
-
The United States Food and Drugs Admi nistration News Release. Accessed April 29
-
The United States Food and Drugs Admi nistration News Release. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm367726. htm. Accessed April 29, 2014
-
(2014)
-
-
-
6
-
-
84907283725
-
-
The United States Food and Drugs Administration. Goal of label changes: better prescribing, safer use of opioids Washington DC, USA. Accessed April 30, 2014
-
The United States Food and Drugs Administration. Goal of label changes: better prescribing, safer use of opioids. 2013. Washington DC, USA. http://www.fda.gov/forconsumers/consumerupdates/ucm367660.htm. Accessed April 30, 2014
-
(2013)
-
-
-
7
-
-
84907283724
-
-
The United States Food and Drugs Administration. List of ex tended-release and long-acting opioid products required to have an opioid REMS. Washington DC, USA. Accessed April 20
-
The United States Food and Drugs Administration. List of ex tended-release and long-acting opioid products required to have an opioid REMS. Washington DC, USA. http://www.fda.gov/drugs/drugsafety/Informationbydrugclass/ucm251735.htm. Accessed April 20, 2014
-
(2014)
-
-
-
8
-
-
84907283723
-
-
United St ates Department of Justice. Drug Enforcement Agency. Drug scheduling. Washington DC, USA. Accessed August 13
-
United St ates Department of Justice. Drug Enforcement Agency. Drug scheduling. Washington DC, USA. http://www.justice.gov/dea/druginfo/ds.shtml. Accessed August 13, 2013
-
(2013)
-
-
-
9
-
-
84907283627
-
-
Purdue Pharma Oxycontin Full Prescribing Information 2014. Stamford, CT, USA. Accessed April 20
-
Purdue Pharma. Oxycontin Full Prescribing Information 2014. Stamford, CT, USA. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022272s022lbl.pdf. Accessed April 20, 2014
-
(2014)
-
-
-
10
-
-
84907283626
-
-
Academy of Managed Care Pharmacy, Common practice in formulary management systems. Academy of Managed Care Pharmacy Alexandria, VA, USA. Accessed April 28, 2014
-
Academy of Managed Care Pharmacy, Common practice in formulary management systems. Academy of Managed Care Pharmacy, 2000. Alexandria, VA, USA. http://www.amcp.org/WorkArea/DownloadAsset. aspx?id= 9274. Accessed April 28, 2014
-
(2000)
-
-
-
11
-
-
84860741571
-
Pharmaceutical technology assessment: Perspectives from payers
-
Leung M, Halpern M, West N. Pharmaceutical technology assessment: perspectives from payers. JMCP 2012;18:256-64
-
(2012)
JMCP
, vol.18
, pp. 256-264
-
-
Leung, M.1
Halpern, M.2
West, N.3
-
12
-
-
84881670427
-
Deciding which drugs get onto the formulary: A value-based approach
-
Seigfried R, Corbo T, Saltzberg M, et al. Deciding which drugs get onto the formulary: a value-based approach. Value Health 2013;16:901-6
-
(2013)
Value Health
, vol.16
, pp. 901-906
-
-
Seigfried, R.1
Corbo, T.2
Saltzberg, M.3
-
13
-
-
12144266162
-
Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population
-
Delate T, Mager, DE, Sheth J. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. AJMC 2005;11:29-36
-
(2005)
AJMC
, vol.11
, pp. 29-36
-
-
Delate, T.1
De, M.2
Sheth, J.3
-
14
-
-
56049086018
-
Prior authorization for biologic diseasemodifying antirheumatic drugs: A description of US Medicaid programs
-
Fischer M, Polinski J, Servi A, et al. Prior authorization for biologic diseasemodifying antirheumatic drugs: a description of US Medicaid programs. Arthritis Rheum 2008;59:1611-7
-
(2008)
Arthritis Rheum
, vol.59
, pp. 1611-1617
-
-
Fischer, M.1
Polinski, J.2
Servi, A.3
-
15
-
-
44449114349
-
Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change
-
Soumeria S, Zhang F, Ross-Degnan D, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Affairs 2008;27:185-95
-
(2008)
Health Affairs
, vol.27
, pp. 185-195
-
-
Soumeria, S.1
Zhang, F.2
Ross-Degnan, D.3
-
16
-
-
77958139493
-
Impact of prior authorization for pregabalin on health plan drug expenditures
-
Bazalo G, Weiss R, Joshi A. Impact of prior authorization for pregabalin on health plan drug expenditures. AJMC 2010;16:S154-9
-
(2010)
AJMC
, vol.16
, pp. S154-S159
-
-
Bazalo, G.1
Weiss, R.2
Joshi, A.3
-
17
-
-
77954096052
-
Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans
-
Margolis J, Cao Z, Onukwugha W, et al. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. AJMC 2010;16:447-56
-
(2010)
AJMC
, vol.16
, pp. 447-456
-
-
Margolis, J.1
Cao, Z.2
Onukwugha, W.3
-
18
-
-
44449116226
-
Medicaid prior authorization and controlledrelease oxycodone
-
Morden N, Zerzan J, Rue T, et al. Medicaid prior authorization and controlledrelease oxycodone. Med Care 2008;46:573-80
-
(2008)
Med Care
, vol.46
, pp. 573-580
-
-
Morden, N.1
Zerzan, J.2
Rue, T.3
-
19
-
-
84877925015
-
Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain
-
Merchant S, Noe L, Howe A, et al. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain . Clin Therapeut 2013;35:359-72
-
(2013)
Clin Therapeut
, vol.35
, pp. 359-372
-
-
Merchant, S.1
Noe, L.2
Howe, A.3
-
20
-
-
84907283625
-
-
US Department of Health and Human Services. Food and Drug Adminstration. FDA actions on OxyContin Products 4/16/2013. FDA news release 2013. Washinton DC. Accessed September 26
-
US Department of Health and Human Services. Food and Drug Adminstration. FDA actions on OxyContin Products 4/16/2013. FDA news release 2013. Washinton DC., http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm348252.htm, Accessed September 26, 2013
-
(2013)
-
-
-
21
-
-
0026639706
-
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
-
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9
-
(1992)
J Clin Epidemiol
, vol.45
, pp. 613-619
-
-
Deyo, R.A.1
Cherkin, D.C.2
Ciol, M.A.3
-
22
-
-
27744568384
-
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
-
Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
-
(2005)
Med Care
, vol.43
, pp. 1130-1139
-
-
Quan, H.1
Sundararajan, V.2
Halfon, P.3
-
26
-
-
84866644230
-
Clinical policy: Critical issues in the prescribing of opioids for adult patients in the emergency department
-
Cantrill S, Brown M, Carlisle R, et al. Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department. Ann Em erg Med 2012;60:499-525
-
(2012)
Ann em Erg Med
, vol.60
, pp. 499-525
-
-
Cantrill, S.1
Brown, M.2
Carlisle, R.3
-
27
-
-
84884181958
-
Opioid use and abuse: A pain clinic perspective
-
Schultz D. Opioid use and abuse: a pain clinic perspective. Minn Med 2013;96:42-4
-
(2013)
Minn Med
, vol.96
, pp. 42-44
-
-
Schultz, D.1
-
28
-
-
84879358492
-
Opioids for the management of non-cancer pain
-
Nelsen D. Opioids for the management of non-cancer pain. J Ark Med Soc 2013;109:252-3
-
(2013)
J Ark Med Soc
, vol.109
, pp. 252-253
-
-
Nelsen, D.1
-
30
-
-
84884174675
-
Finding a feasible solution states employ different legislative strategies to curb misuse
-
Milhofer J. Finding a feasible solution. States employ different legislative strategies to curb misuse. Minn Med 2013;96:52-4
-
(2013)
Minn Med
, vol.96
, pp. 52-54
-
-
Milhofer, J.1
-
31
-
-
84884218515
-
A call for evidence-based medical treatment of opioid dependence in the United States and Canada
-
Nosyk B, Anglin M, Brissette S, et al. A call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health Aff 2013;32:1462-9
-
(2013)
Health Aff
, vol.32
, pp. 1462-1469
-
-
Nosyk, B.1
Anglin, M.2
Brissette, S.3
-
33
-
-
0033710389
-
What is the real cost of prior authorization
-
Reissman D. What is the real cost of prior authorization? Drug Benefit Trends 2000;12:22-4
-
(2000)
Drug Benefit Trends
, vol.12
, pp. 22-24
-
-
Reissman, D.1
-
34
-
-
84907283624
-
Manage medical advances with automated prior authorization
-
Accessed November 20, 2013
-
Moeller D. Manage medical advances with automated prior authorization. Managed Executive 2009. http://managedhealthcareexecutive.modernmedicine. com/mhe/article/articleDetail.jsp?id=615491. Accessed November 20, 2013
-
(2009)
Managed Executive
-
-
Moeller, D.1
-
35
-
-
34250875798
-
Prior authorization of newer insomnia medications in managed care is it cost saving
-
Balkrishnan R, Joish V, Bhosle MJ, et al. Prior authorization of newer insomnia medications in managed care: is it cost saving? J Clin Sleep Med 2007;3:393-8
-
(2007)
J Clin Sleep Med
, vol.3
, pp. 393-398
-
-
Balkrishnan, R.1
Joish, V.2
Bhosle, M.J.3
-
36
-
-
0033869399
-
A comparison of two methods for estimating the health care costs of epilepsy
-
Frost FJ, Hurley JS, Petersen HV, et al. A comparison of two methods for estimating the health care costs of epilepsy. Epilepsia 2000;41:1020-6
-
(2000)
Epilepsia
, vol.41
, pp. 1020-1026
-
-
Frost, F.J.1
Hurley, J.S.2
Petersen, H.V.3
-
37
-
-
77954715172
-
Cost of diabetes: Comparison of diseaseattributable and matched cohort cost estimation methods
-
Tunceli O, Wade R, Gu T, et al. Cost of diabetes: comparison of diseaseattributable and matched cohort cost estimation methods. CMRO 2010;26:1827 -34
-
(2010)
CMRO
, vol.26
, pp. 1827-1834
-
-
Tunceli, O.1
Wade, R.2
Gu, T.3
|